Aurinia: Lupkynis Is A Cash Cow, But Competition And Patent Risks Cap The Upside
Aurinia Pharmaceuticals Inc AUPH
$16.44
▼ -0.93%
($-0.16)
Open
$16.60
Prev Close
$16.60
Day Range
$16.31 – $16.78
52W Range
$10.34 – $19.25
Market Cap
$2.19B
P/E (TTM)
6.99
Beta
1.42
EPS (TTM)
$2.29
📋 Company Profile
| Industry | Biotechnology |
| Country | CA |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2001-07-16 |
| Shares Out. | 128,600,000 |
| Website | auriniapharma.com ↗ |
| Phone | 12507442487 |
| Employees | 128 |
| Revenue | $83.2M |
| Gross Profit | $76.7M |
| Net Income | $37.4M |
| Free Cash Flow | $175.1M |
| Total Assets | $792.3M |
| Total Liabilities | $177.4M |
| Equity | $614.9M |
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Aurinia Pharmaceuticals Inc is a publicly traded company under the ticker symbol AUPH on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-09-01)